Fibromyalgia clinical design
Executive Summary
The arthritis committee will meet June 23 to discuss clinical trial design for therapies intended to treat fibromyalgia, including important disease endpoints. Pfizer has been conducting studies of its Neurontin successor agent pregabalin in fibromyalgia (1"The Pink Sheet" Nov. 4, 2002, p. 8). The meeting will begin at 8 a.m. on both days at the Holiday Inn in Bethesda, Md. [For 2webcasts, live video or videotapes of these and other meetings, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Pfizer To Audit Managed Care Grants Under Lipitor “Best Price” Settlement
Pfizer will fund an independent review of its managed care expenditures and best price calculation practices as part of a settlement of a Department of Justice investigation into Lipitor price reporting
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.